Immutep (ASX:IMM) has announced that the open-label safety lead-in of its integrated AIPAC-003 Phase 2/3 trial evaluating 90mg of eftilagimod alpha (efti) in combination with paclitaxel has been completed with no safety or tolerability issues. …
Immutep announces the completion of key stage of AIPAC-003 trial in metastatic breast cancer
November 6, 2023 Australian Biotech
Latest Video
New Stories
-
Astellas bets up to US$1.34 billion on Melbourne startup's cancer candidate
October 28, 2026 - - Latest News -
The stakes are very high on access in a contested budget environment
October 28, 2026 - - Latest News -
Managing an agreement negotiation as a 'prisoner of circumstance'
October 28, 2026 - - Latest News -
MSAC suggests minister skip HTA and make policy fix to ensure access to this technology
October 28, 2026 - - Latest News -
AusBiotech takes 15-year refund limit fight to the Senate as R&D tax bill lands
October 28, 2026 - - Latest News -
Lung scarring killing 11 Australians a day, with one in five cases traced to work
October 28, 2026 - - Latest News -
Company rebates fall for the first time in years, lifting net PBS costs
October 27, 2026 - - Latest News